277 related articles for article (PubMed ID: 32279037)
1. In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models.
Das D; Xie L; Wang J; Shi J; Hong J
Bioorg Chem; 2020 Jun; 99():103790. PubMed ID: 32279037
[TBL] [Abstract][Full Text] [Related]
2. Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC).
Pawara R; Ahmad I; Nayak D; Wagh S; Wadkar A; Ansari A; Belamkar S; Surana S; Nath Kundu C; Patil C; Patel H
Bioorg Chem; 2021 Oct; 115():105234. PubMed ID: 34399322
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors.
Zhang L; Yang Y; Zhou H; Zheng Q; Li Y; Zheng S; Zhao S; Chen D; Fan C
Eur J Med Chem; 2015 Sep; 102():445-63. PubMed ID: 26310890
[TBL] [Abstract][Full Text] [Related]
4. Discovery of new quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors and their anticancer activities - Part 1.
Das D; Xie L; Wang J; Xu X; Zhang Z; Shi J; Le X; Hong J
Bioorg Med Chem Lett; 2019 Feb; 29(4):591-596. PubMed ID: 30600209
[TBL] [Abstract][Full Text] [Related]
5. Discovery of highly potent and selective EGFR
Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
Zhao L; Fan T; Shi Z; Ding C; Zhang C; Yuan Z; Sun Q; Tan C; Chu B; Jiang Y
Eur J Med Chem; 2021 Mar; 213():113173. PubMed ID: 33493830
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2.
Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS
Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of cinnamamide-quinazoline derivatives as potential EGFR inhibitors to reverse T790M mutation.
Zhang B; Xu Z; Liu Q; Xia S; Liu Z; Liao Z; Gou S
Bioorg Chem; 2021 Dec; 117():105420. PubMed ID: 34655841
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
[TBL] [Abstract][Full Text] [Related]
10. New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers.
Liu Z; Wang L; Feng M; Yi Y; Zhang W; Liu W; Li L; Liu Z; Li Y; Ma X
Bioorg Chem; 2018 Apr; 77():593-599. PubMed ID: 29482151
[TBL] [Abstract][Full Text] [Related]
11. Novel 4-arylaminoquinazolines bearing
Zhang Y; Chen L; Li X; Gao L; Hao Y; Li B; Yan Y
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1668-1677. PubMed ID: 31530043
[TBL] [Abstract][Full Text] [Related]
12. AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo.
Xie H; Lin L; Tong L; Jiang Y; Zheng M; Chen Z; Jiang X; Zhang X; Ren X; Qu W; Yang Y; Wan H; Chen Y; Zuo J; Jiang H; Geng M; Ding J
PLoS One; 2011; 6(7):e21487. PubMed ID: 21789172
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H
Zheng YG; Zhang WQ; Meng L; Wu XQ; Zhang L; An L; Li CL; Gao CY; Xu L; Liu Y
Eur J Med Chem; 2020 Sep; 202():112522. PubMed ID: 32619886
[TBL] [Abstract][Full Text] [Related]
15. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.
Li D; Ambrogio L; Shimamura T; Kubo S; Takahashi M; Chirieac LR; Padera RF; Shapiro GI; Baum A; Himmelsbach F; Rettig WJ; Meyerson M; Solca F; Greulich H; Wong KK
Oncogene; 2008 Aug; 27(34):4702-11. PubMed ID: 18408761
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC.
Zhou P; Chen G; Gao M; Wu J
Bioorg Med Chem; 2018 Dec; 26(23-24):6135-6145. PubMed ID: 30442506
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFR
Ding S; Dong X; Gao Z; Zheng X; Ji J; Zhang M; Liu F; Wu S; Li M; Song W; Shen J; Duan W; Liu J; Chen Y
Bioorg Chem; 2022 Jan; 118():105471. PubMed ID: 34798457
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR
Li J; An B; Song X; Zhang Q; Chen C; Wei S; Fan R; Li X; Zou Y
Eur J Med Chem; 2021 Feb; 212():113019. PubMed ID: 33429247
[TBL] [Abstract][Full Text] [Related]
19. Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.
Song J; Jang S; Lee JW; Jung D; Lee S; Min KH
Bioorg Med Chem Lett; 2019 Feb; 29(3):477-480. PubMed ID: 30554954
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Anti-Proliferation Activity Evaluation of Novel 2-Chloroquinazoline as Potential EGFR-TK Inhibitors.
Zheng Q; Xu XB; Jin H; Zhang W; Rao GW
Chem Biodivers; 2021 Nov; 18(11):e2100478. PubMed ID: 34510749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
